Vancouver, British Columbia, August 31, 2023 – Lophos Holdings Inc. (“Lophos“, or the “Company“) is pleased to announce that its common shares have been approved for listing on the Canadian Securities Exchange (the “CSE“) and the Company expects to commence trading on the CSE on or around September 06, 2023,
NAPANEE, Ontario, Aug. 25, 2023 (GLOBE NEWSWIRE) — Lophos Holdings Inc. is pleased to announce that its wholly owned subsidiary, Lophos Pharmaceuticals Corp., has received its Controlled Substances Dealers License (CSDL) from Health Canada, effective as of August 23, 2023. The Controlled Substances Dealers License (CSDL) permits Lophos Pharmaceuticals to
Toronto, Ontario–(Newsfile Corp. – March 21, 2022) – Lophos Pharmaceuticals Inc., a Canadian psychedelic research company focused on cultivation and drug development, engages KGK Science Inc. to evaluate a path to market for sustainably-grown peyote-derived natural health products (NHPs). Peyote has legal status in Canada, but mescaline – the drug derived from
Napanee, Ontario–(Newsfile Corp. – April 12, 2022) – Lophos Pharmaceuticals Corp. , a biosciences research and development company, will be participating in the Benzinga Psychedelics Capital Conference, which will take place on April 19 at the Fontainebleau Miami Beach. Claire Stawnyczy, CEO will be speaking at 01:00 PM ET on April 19th. Interested parties can
Toronto, Ontario–(Newsfile Corp. – April 28, 2022) – Lophos Pharmaceuticals Corp., Lophos is a Canadian psychedelic research company focused on peyote and its derivatives such as mescaline. Peyote, an endangered plant species with a long history of therapeutic use has legal status in Canada, but mescaline, a powerful psychedelic molecule derived from the plant,
Toronto, Ontario–(Newsfile Corp. – May 10, 2022) – Lophos Pharmaceuticals Corp., a Canadian psychedelic research company is scheduled to present at the upcoming Lift & Co. Expo next week, Friday, May 13th. The feature presentation titled, “Nature’s Medicine: Peyote’s Place in the Psychedelic Industry,” is scheduled for 11:30am. Claire Stawnyczy, President & CEO
Lophos Pharma is a Canadian peyote-focused psychedelics company. It was co-founded by wife and husband duo Claire and Evan Stawnyczy to explore mescaline’s potential in a range of indications, optimize the cultivation of peyote, and preserve the plant. It’s an ambitious plan in an emerging sector that has so far embraced
TORONTO, Feb. 17, 2022 (GLOBE NEWSWIRE) — Lophos Holdings (The “Company”) is pleased to provide an update on its wholly owned subsidiary Lophos Pharmaceuticals (“Lophos”). Lophos is a psychedelic research company primarily focused on novel therapeutic treatments derived from Peyote (Lophophora williamsii). Lophos has made significant strides in launching operations at their
TORONTO, Jan. 21, 2022 (GLOBE NEWSWIRE) — Greenridez 2.0 Acquisitions Corp. (the “Company“) is pleased to announce that it has completed its acquisition of psychedelic research company Lophos Pharma (“Lophos”). Lophos Pharma is a psychedelic research company primarily focused on novel therapeutic treatments derived from Peyote (Lophophora williamsii). The Company strongly supports
Vancouver, British Columbia, August 31, 2023 – Lophos Holdings Inc. (“Lophos“, or the “Company“) is pleased to announce that its common shares have been approved for listing on the Canadian Securities Exchange (the “CSE“) and the Company expects to commence trading on the CSE on or around September 06, 2023,
NAPANEE, Ontario, Aug. 25, 2023 (GLOBE NEWSWIRE) — Lophos Holdings Inc. is pleased to announce that its wholly owned subsidiary, Lophos Pharmaceuticals Corp., has received its Controlled Substances Dealers License (CSDL) from Health Canada, effective as of August 23, 2023. The Controlled Substances Dealers License (CSDL) permits Lophos Pharmaceuticals to
Toronto, Ontario–(Newsfile Corp. – March 21, 2022) – Lophos Pharmaceuticals Inc., a Canadian psychedelic research company focused on cultivation and drug development, engages KGK Science Inc. to evaluate a path to market for sustainably-grown peyote-derived natural health products (NHPs). Peyote has legal status in Canada, but mescaline – the drug derived from
Napanee, Ontario–(Newsfile Corp. – April 12, 2022) – Lophos Pharmaceuticals Corp. , a biosciences research and development company, will be participating in the Benzinga Psychedelics Capital Conference, which will take place on April 19 at the Fontainebleau Miami Beach. Claire Stawnyczy, CEO will be speaking at 01:00 PM ET on April 19th. Interested parties can
Toronto, Ontario–(Newsfile Corp. – April 28, 2022) – Lophos Pharmaceuticals Corp., Lophos is a Canadian psychedelic research company focused on peyote and its derivatives such as mescaline. Peyote, an endangered plant species with a long history of therapeutic use has legal status in Canada, but mescaline, a powerful psychedelic molecule derived from the plant,
Toronto, Ontario–(Newsfile Corp. – May 10, 2022) – Lophos Pharmaceuticals Corp., a Canadian psychedelic research company is scheduled to present at the upcoming Lift & Co. Expo next week, Friday, May 13th. The feature presentation titled, “Nature’s Medicine: Peyote’s Place in the Psychedelic Industry,” is scheduled for 11:30am. Claire Stawnyczy, President & CEO
Lophos Pharma is a Canadian peyote-focused psychedelics company. It was co-founded by wife and husband duo Claire and Evan Stawnyczy to explore mescaline’s potential in a range of indications, optimize the cultivation of peyote, and preserve the plant. It’s an ambitious plan in an emerging sector that has so far embraced
TORONTO, Feb. 17, 2022 (GLOBE NEWSWIRE) — Lophos Holdings (The “Company”) is pleased to provide an update on its wholly owned subsidiary Lophos Pharmaceuticals (“Lophos”). Lophos is a psychedelic research company primarily focused on novel therapeutic treatments derived from Peyote (Lophophora williamsii). Lophos has made significant strides in launching operations at their
TORONTO, Jan. 21, 2022 (GLOBE NEWSWIRE) — Greenridez 2.0 Acquisitions Corp. (the “Company“) is pleased to announce that it has completed its acquisition of psychedelic research company Lophos Pharma (“Lophos”). Lophos Pharma is a psychedelic research company primarily focused on novel therapeutic treatments derived from Peyote (Lophophora williamsii). The Company strongly supports